Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.
A simple and rapid method with high performance liquid chromatography/tandem mass spectrometry is described for the quantitation of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma. A protein precipitation extraction procedure was applied to 50 μL of plasma. Chromatographic separation of the two analytes, and the internal standard [(2)H(3)(13)C]-sorafenib, was achieved on a C(18) analytical column and isocratic flow at 0.3 mL/min for 4 min. Mean within-run and between-run precision for all analytes were <6.9% and accuracy was <5.3%. Calibration curves were linear over the concentration range of 50-10,000 ng/mL for sorafenib and 10-2500 ng/mL for sorafenib N-oxide. This method allows a specific, sensitive, and reliable determination of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma in a single analytical run.
Li
Lie
L
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Zhao
Ming
M
Navid
Fariba
F
Pratz
Keith
K
Smith
B Doug
BD
Rudek
Michelle A
MA
Baker
Sharyn D
SD
D001557:Benzenesulfonates / Q000097:blood* / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives; D010087:Oxides / Q000097:blood* / Q000378:metabolism; D010671:Phenylurea Compounds; D011725:Pyridines / Q000097:blood* / Q000378:metabolism*; D000077157:Sorafenib; D053719:Tandem Mass Spectrometry / Q000379:methods*
D001557:Benzenesulfonates; D010087:Oxides; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib